Table 2.
Hazard Ratios for all breast cancer incidence in the tamoxifen arm according to side effects at 6 months and menopausal status.
| Side effect status | Overall |
Postmenopausal |
Premenopausal |
|||
|---|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Hot flushes | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 1.26 (0.98–1.62) | 0.08 | 1.59 (1.12–2.26) | 0.01 | 0.89 (0.61–1.32) | 0.57 |
| Vaginal discharge | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 0.73 (0.49–1.07) | 0.11 | 0.63 (0.38–1.07) | 0.09 | 0.86 (0.48–1.55) | 0.62 |
| Vaginal dryness | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 0.88 (0.56–1.40) | 0.59 | 0.89 (0.50–1.58) | 0.70 | 0.84 (0.39–1.82) | 0.66 |